FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to obtaining recombinant MHC class II molecules, and can be used in medicine. Recombinant MHC class II molecule includes: (i) all or part of the extracellular portion of an MHC class II α-chain; (ii) all or part of the extracellular portion of an MHC class II β-chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the α2 domain of said α-chain and the β2 domain of said β-chain, wherein said cysteine residues are not present in native MHC class II α2 and β2 domains, and obtained recombinant molecule does not include a leucine zipper motif.
EFFECT: invention enables to obtain recombinant MHC class II molecules stabilized by disulphide bond.
32 cl, 10 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| HUMANIZED T-CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | 2016 |
|
RU2732628C2 |
| SINGLE-STRAND RECOMBINANT T-CELL RECEPTORS | 2003 |
|
RU2355703C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES | 2012 |
|
RU2660564C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX | 2012 |
|
RU2797549C2 |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2653433C2 |
| IMMUNOCONJUGATES FOR THE SPECIFIC INDUCTION OF T CELL CYTOTOXICITY AGAINST TARGET CELLS | 2016 |
|
RU2746021C2 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
